Glaxo Subsidiary Stiefel’s Former CEO Faces Securities Fraud Charges
This article was originally published in The Tan Sheet
Executive Summary
The Securities and Exchange Commission alleges Charles Stiefel, former chairman and CEO of family-owned Stiefel Labs, did not disclose to employee-shareholders material information on the value of the firm’s shares as the firm bought back shares before being acquired by GlaxoSmithKline.